chapter 01 · the validation spine
The nine BMV parameters · five regulators.
Quick-reference grid of all nine parameters · then the cross-regulator comparison drilldown for each. ICH M10 · FDA · EMA · WHO · ANVISA. The flagship chapter for the analytical spine.
/ 00
The deep reference: iFeed.bioanalytical.
Already published · liveiFeed maintains a deep reference for bioanalytical method validation under the sub-brand iFeed.bioanalytical. The foundation document is a cross-source comparison across five source families (ICH M10 · FDA · EMA · WHO/PQT · ANVISA) and the nine BMV pillars that form the validation spine. Built on official BMV sources, historical comparison documents, and production-floor substrate assembled across CRO, sponsor, and MedTech work.
/ Foundation document
5 regulators · 9 BMV pillars · one reference.
Pick a pillar. Read the convergence/divergence summary. Compare 5 regulators side-by-side. Each acceptance criterion highlighted. Designed for the validation scientist · the QA auditor · the cross-region sponsor.
ICH M10FDAEMA Rev 1 · historicalWHO/PQTANVISA
/ 00b
The nine BMV pillars.
The validation spineThese nine pillars are the validation areas a bioanalytical method is generally expected to address, as applicable to method type, matrix, modality, and study purpose. Below: a quick-reference grid of all nine parameters · then the cross-source comparison drilldown for each. Selectivity and matrix effect are especially important places to check source-specific expectations.
Quick reference · the nine parameters.
/ 3.1
Selectivity & specificity.
Can the method tell analyte apart from matrix interference? Current source comparison should distinguish chromatographic and ligand-binding assay expectations and identify the applicable source family before setting the panel size.
/ 3.2
Calibration curve & range.
Six non-zero calibrators, blank, zero. ±15% nominal except LLOQ at ±20%. The autobiography of the method.
/ 3.3
Accuracy & precision.
Within-run, between-run. ±15% nominal accuracy, ≤15% CV precision. Four QC concentration levels covering the validation range.
/ 3.4
Carry-over.
Response in blank after ULOQ injection ≤20% LLOQ. Where chromatographic methods most often surprise QA.
/ 3.5
Matrix effect.★
Where source-family divergence can run deep. Matrix-effect evidence should be tied to the current source text, method type, matrix, and jurisdictional context instead of relying on a single global shortcut.
/ 3.6
Stability.
Bench-top, freeze-thaw, long-term, stock solution, processed sample. Stability is often revisited later because storage conditions, sample handling, and raw-data records must remain explainable across the study lifecycle.
/ 3.7
Dilution integrity.
For samples above ULOQ. Dilution factor up to 10× typically validated. Critical for dose-escalation and pediatric formulations.
/ 3.8
Incurred sample reanalysis (ISR).
10% of samples reanalysed in pivotal studies. ≥67% within 20% of original. The post-validation reality check.
/ 3.9
Reanalysis & in-study.
Run acceptance criteria · 75% of QCs and 67% per concentration. Authority for repeats. Documented per study.
Cross-regulator comparison · ICH M10 · FDA · EMA · WHO · ANVISA.
Source boundary: This comparison uses ICH M10 as the current harmonised anchor, FDA and EMA pages as official public anchors, and WHO/PQT plus ANVISA as source families that need current-context checking for region-specific use. EMA Rev.1 is retained for historical comparison only.
Official anchors: ICH M10 Step 4 · FDA M10 · FDA 2018 BMV guidance · EMA ICH M10.
ICH M10
FDA
EMA Rev 1
WHO TRS 996
ANVISA
/ 3.1 Selectivity & specificity.Can the method tell analyte apart from matrix interference? +
At a glance · convergence vs divergence
CONVERGE
The core expectation is differentiation of analyte from endogenous matrix components. Current public wording should anchor the exact acceptance criteria to the source used for the target region and method type.
DIVERGE
ICH M10 and FDA source text distinguish chromatographic and ligand-binding assay expectations. EMA Rev 1 is useful historical context, while ANVISA and WHO/PQT details should be checked against the current source stack before use in a public checklist.
ICH M102022
§3.2.1 / §4.2.2 · harmonised
Distinguishes chromatographic and ligand-binding assay source expectations; exact panel design should be checked against the current ICH M10 text and method type.
Acceptance criteriaRead directly from ICH M10 for target method type
FDA2018
US source anchor
Useful US source anchor for selectivity expectations; exact LBA source-count and pass criteria should be read directly in the FDA guidance and ICH M10 before checklist use.
Acceptance criteriaRead directly from FDA + ICH M10
EMA Rev 12011
Superseded by M10
§4.1.1 · 6 lots historically · cover page now carries supersession notice referencing M10.
Acceptance criteriaSame blank · 6 lots across CC and LBA · superseded
WHO TRS 9962016
Annex 9 · multisource
WHO/PQT use should be checked against the current WHO source and target prequalification context before applying acceptance criteria.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific claims should be mapped from the current ANVISA text before public use. Historical workshop or presentation material should remain internal unless source-linked.
Acceptance criteriaCurrent source check needed
Reviewer’s eye
For M10-aligned LBA packages, check whether the selectivity panel reflects current ICH/FDA expectations rather than relying only on a historical EMA-style six-source approach. If an older package is reused, document the source basis and transition rationale.
/ 3.2 Calibration curve & range.Concentration-response model · 6 non-zero levels · ±15% / ±20% LLOQ. +
At a glance · convergence vs divergence
CONVERGE
ICH M10 and major public guidance sources converge around calibration performance principles. Exact thresholds should be checked against the target method type and current source text.
DIVERGE
M10 §3.3.2 closes a regression-model lock loophole pre-2022 EMA practice tolerated. LBA cards have wider range tolerances (±20% / ±25% LLOQ-ULOQ).
ICH M102022
§3.3.2 closes regression loophole
CC: ±15% / ±20% LLOQ · 75% pass · 6 levels. LBA: ±20% / ±25% LLOQ-ULOQ.
Acceptance criteria±15% · ±20% LLOQ · 75% pass · 6 non-zero
FDA2018
Final · same thresholds
US source anchor for calibration and run-acceptance logic; use alongside ICH M10 and the target submission context.
Acceptance criteria±15% · ±20% LLOQ · 75% pass · 6 levels
EMA Rev 12011
Superseded · regression flexibility
§4.1.4 · same nominal thresholds · regression model flexibility now closed by M10.
Acceptance criteriaSame numerical thresholds · regression-lock now per M10
WHO TRS 9962016
Annex 9 · BE context
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific implementation details should be source-checked before public checklist use.
Acceptance criteria±15% · ±20% LLOQ
/ 3.3 Accuracy & precision.Within-run · between-run · LLOQ included · LBA needs 5 QC levels. +
At a glance · convergence vs divergence
CONVERGE
Accuracy and precision are core pillars across source families. Public checklist values should be method-type specific and source-anchored.
DIVERGE
LBA accuracy and precision evidence differs from chromatographic-method evidence. Exact run numbers, QC levels, and acceptance thresholds should be read directly from the current ICH M10 and FDA source text before public checklist translation.
ICH M102022
§3.2.5 / §4.2.4 · raised LBA bar
CC: 3 reps × 6 lots. LBA: 5 QC levels (LLOQ · LowQC · MidQC · HighQC · ULOQ-near).
Acceptance criteriaCC: ±15% · 15% CV · LBA: ±20% · 20% CV · 5 QC
FDA2018
§IV · 6 A&P runs LBA
US source anchor for accuracy and precision expectations; exact LBA/chromatographic differences should be read directly in the source text.
Acceptance criteria±15% / 15% CV CC · 6 runs LBA · 3 runs CC
EMA Rev 12011
Superseded · 4 LBA QC levels
§4.1.5 · 4 QC levels (LLOQ · Low · Mid · High) for LBAs · M10 raised to 5.
Acceptance criteria±15% / 15% CV · 4 LBA QC levels historically
WHO TRS 9962016
Annex 9 · defers
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific implementation details should be source-checked before public checklist use.
Acceptance criteriaCurrent source check needed
/ 3.4 Carry-over.Prevention + assessment in serial-injection workflows. +
At a glance · convergence vs divergence
CONVERGE
Carry-over control is a shared expectation, but public checklist thresholds should be source-anchored to the applicable method and region.
DIVERGE
Brazil-specific injection-sequence claims need current ANVISA source confirmation before public use.
ICH M102022
§3.2.6 · 1 blank after ULOQ
Single blank after highest standard · prevention measures encouraged at method development.
Acceptance criteriaBlank after ULOQ ≤20% LLOQ · ≤5% IS
FDA2018
Aligned · single blank
Same single-blank approach · same thresholds.
Acceptance criteria≤20% LLOQ analyte · ≤5% IS
EMA Rev 12011
Superseded · same numbers
§4.1.2 · same threshold approach.
Acceptance criteria≤20% LLOQ analyte · ≤5% IS
WHO TRS 9962016
Defers
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific injection-sequence requirements should be mapped from current ANVISA source text before public checklist use.
Acceptance criteriaCurrent source check needed
/ 3.5 Matrix effect.★Per-source evidence · historical EMA framing · Brazil-specific source check. +
At a glance · convergence vs divergence · the deepest pillar
CONVERGE
All recognise ion suppression / enhancement as the central LC-MS/MS quality concern.
DIVERGE
M10 §3.2.3 moved current harmonised practice away from the historical EMA Rev 1 IS-normalised Matrix Factor framing toward per-source A&P. Brazil-specific fixed-lot composition should be checked against the current ANVISA source stack before being used in public-facing checklists.
ICH M102022
§3.2.3 · replaced EMA IS-norm MF
Per-source accuracy and precision evidence is the current harmonised anchor; exact lot and replicate design should be checked against the method type and source text.
Acceptance criteria3 × 6 lots · ±15% · 15% CV
FDA2018
Pre-M10 · per-source approach
FDA 2018 is a useful US anchor for per-source matrix-effect evidence and should be read alongside ICH M10.
Acceptance criteriaPer-source A&P · 6 lots · ±15% / 15% CV
EMA Rev 12011
historical · superseded
Historical EMA Rev.1 framing is retained only to explain older reports. Current public interpretation should anchor to EMA's ICH M10 page.
Acceptance criteriaHistorical context only
WHO TRS 9962016
Defers
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific matrix composition requirements should be mapped from current ANVISA source text before public checklist use.
Acceptance criteriaCurrent source check needed
Reviewer’s eye
For M10-aligned packages, check whether matrix-effect evidence is documented in the current per-source A&P style rather than relying only on historical EMA Rev 1 IS-normalised MF logic. If the package was built pre-M10, a transition rationale or alignment note may be needed.
/ 3.6 Stability.Stock · working solution · matrix · freeze-thaw · long-term · benchtop. +
At a glance · convergence vs divergence
CONVERGE
Stability evidence generally covers stock solution, working solution, freeze-thaw, short-term, long-term, and processed-sample conditions.
DIVERGE
WHO/PQT and ANVISA-specific stability and raw-data expectations need current source confirmation before being converted into public checklist criteria.
ICH M102022
§3.2.8 · standard stability suite
Stock · working · matrix · F/T · benchtop · long-term · processed sample stability.
Acceptance criteria±15% across all stability variants
FDA2018
Aligned · same suite
Same stability matrix · same threshold.
Acceptance criteria±15%
EMA Rev 12011
Superseded · same approach
§4.1.9 · same suite.
Acceptance criteria±15%
WHO TRS 9962016
current source check
WHO/PQT raw-data and stability expectations should be read directly in current WHO source material before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific stock-solution stability criteria should be source-checked before public checklist use.
Acceptance criteriaCurrent source check needed
Reviewer’s eye
For Brazil-bound submissions, check the current ANVISA source before applying global default stability criteria. For WHO/PQT submissions, preserve electronic chromatographic raw data and avoid relying on printed chromatograms as the only evidence record.
/ 3.7 Dilution integrity.Validity for above-ULOQ samples · method-type source check. +
At a glance · convergence vs divergence
CONVERGE
Dilution integrity asks whether above-range samples can be diluted back into a validated range without biasing the result.
DIVERGE
Method-type differences, especially LBA dilution design, should be read directly from ICH M10. Brazil-specific implementation should be source-checked before public use.
ICH M102022
§3.2.7 / §4.2.6
Above-range samples should be diluted within the validated range. LBA-specific dilution design should be read directly from ICH M10.
Acceptance criteriaRead directly from ICH M10 for method type
FDA2018
Aligned
Same approach.
Acceptance criteria±15%
EMA Rev 12011
Superseded
§4.1.7 · same threshold.
Acceptance criteria±15%
WHO TRS 9962016
Defers
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific dilution-integrity handling should be source-checked before public checklist use.
Acceptance criteriaCurrent source check needed
/ 3.8 Incurred sample reanalysis (ISR).Real-sample reproducibility · source-anchored acceptance logic. +
At a glance · convergence vs divergence
CONVERGE
ISR is a core real-sample reproducibility control in modern BMV practice. Acceptance logic should be method-type specific and anchored to the applicable source.
DIVERGE
Historical ANVISA discussion material should not be used as a current public claim unless it is paired with the current ANVISA source.
ICH M102022
§3.3.4 · canonical
Defines ISR planning and acceptance logic for study-sample reproducibility; exact sampling formula and thresholds should be read directly from ICH M10.
Acceptance criteriaRead directly from ICH M10 for method type
FDA2018
Aligned · 20% / 67% rule
Same threshold approach.
Acceptance criteria20% / 67% CC · 30% / 67% LBA
EMA Rev 12011
§6 · same thresholds
Historical EMA Rev.1 section shows why ISR became prominent in EU review practice; current public interpretation should anchor to EMA's ICH M10 page.
Acceptance criteria20% / 67%
WHO TRS 9962016
Annex 9 BE context
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific ISR handling should be source-checked before public checklist use.
Acceptance criteriaCurrent source check needed
/ 3.9 Reanalysis & in-study.When can you re-test a study sample · predefined reasons and audit trail. +
At a glance · convergence vs divergence
CONVERGE
Reanalysis reasons should be predefined, controlled, and visible in the study record. Late, undocumented, or convenience-driven retesting weakens the evidence story.
DIVERGE
Brazil-specific reanalysis constraints should be checked against current ANVISA source text before public checklist translation.
ICH M102022
§3.3.4 · example list
Provides examples of reanalysis triggers; teams should define and control the applicable list in SOPs and study documents.
Acceptance criteriaExample list · pre-defined SOP
FDA2018
Aligned · open list
Same approach.
Acceptance criteriaExample list · pre-defined SOP
EMA Rev 12011
§5.4 · open list
Same approach.
Acceptance criteriaExample list
WHO TRS 9962016
Defers
Use current WHO/PQT source for target-program criteria before public checklist translation.
Acceptance criteriaCurrent source check needed
ANVISAcurrent source check
Brazil-specific source stack
Brazil-specific reanalysis limits should be source-checked before public checklist use.
Acceptance criteriaCurrent source check needed
Reviewer’s eye
For Brazil-bound submissions, compare the global reanalysis SOP with the current ANVISA source and document any Brazil-specific constraints. Avoid assuming that a global reanalysis reason list will be accepted unchanged in every jurisdiction.
/ S
Source register.
official anchors · interpretation kept separateThis bioanalytical page uses official guidance as the source layer and separates iFeed interpretation from regulator text. Jurisdiction-specific details should be checked against the current regulator page before use in submissions, audits, or public checklists.
EMA
ICH M10 EU page.
EMA ICH M10 scientific guideline. Earlier EMA BMV guidance should be marked as historical where used for comparison.